Director PARMAR KUSH sold 200,000 shares of TRDA at $8.80 on 2025-11-14 for $1.76M, reducing stake by 6.3% to 2.96M shares.
PARMAR KUSH, a Director, executed a sale of 200,000 shares at $8.80 per share on 2025-11-14, reducing his holdings from 3.16M shares to 2.96M shares. The sale occurs at a price 59.2% below the 52-week high of $21.59, coinciding with a sharp 50.3% gain over the prior 30 days and 66.1% gain over 90 days. Entrada Therapeutics is a preclinical-stage company burning substantial cash (net income: $-44.1M in the latest quarter) against minimal revenue ($1.6M quarterly), which may constrain liquidity for many months ahead. The combination of recent price momentum recovery, a significant stake reduction by a director with access to material nonpublic information, and the company's unprofitable burn trajectory warrants investor scrutiny of whether the director's assessment of near-term prospects has shifted.